

## **BIOTISSUE CONTRIBUTES TO THE 8<sup>TH</sup> ICRS CONGRESS IN MIAMI**

Zurich, 24 May 2009

**The German-Swiss biotechnology company BioTissue presents the most recent clinical data and developments of its innovative approaches for cartilage repair, based on the company's own tissue regeneration technologies, at the ICRS (International Cartilage Repair Society) meeting in Miami.**

Cartilage degeneration affects millions of people worldwide. In addition to the everyday problems and limitations of the patients' lives, these conditions have a significant impact on health costs.

The ICRS is the most important worldwide organization devoted to cartilage regeneration. The conference, organized every 18 months, is particularly concerned with the most modern therapeutic options for cartilage defects.

More than 1500 scientists and medical doctors from around the world will discuss the latest developments in this area for 3 days in Miami.

The BioTissue Symposium is marking the leading position of the company in the field of cartilage regeneration.

Moderated by Professor Rene Verdonk, three worldwide acknowledged opinion-leaders report on their clinical experiences with BioTissue products.

Dr. Christoph Erggelet (Switzerland) presents the 4 years follow up data of BioTissue's cell based product **BioSeed®-C** for the treatment of traumatic and degenerative cartilage defects.

Dr. Thore Zantop (Germany) reports on the first clinical experiences, arthroscopic fixation and biomechanical data of the companies new product **chondrotissue®**

Prof. Rene Verdonk (Belgium) talks about his experiences and the recently started multi-centre international clinical study with **chondrotissue®**.

For all additional information:

**BioTissue Press Service  
Media Impact**

Rue de Lausanne 42 – 1201 Geneva

Email: [info@mediainpact.ch](mailto:info@mediainpact.ch)

Tel. 022 732 59 97 – Fax. 022 738 62 01